That's a matter for the generics. They have to approach, next, the patentees and make arrangements with the Commissioner of Patents. So there's work to be done on the patent side.
On the food and drug side, they're ready to go in the sense that we think it's safe, efficacious, and of high quality. The differentiating features are there. The labels are all set. So our part is complete.
It's really up to the negotiating part to find the country to provide to and to have those licensing discussions. Those would be the next steps.